The historical rank and industry rank for Sangui Biotech International's EV-to-FCF or its related term are showing as below:
SGBI's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.05 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sangui Biotech International's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangui Biotech International's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sangui Biotech International's EV-to-FCF falls into.
Sangui Biotech International EV-to-FCF Calculation
Sangui Biotech International's current Enterprise Value is $0.00 Mil.
Sangui Biotech International's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangui Biotech International (OTCPK:SGBI) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sangui Biotech International's PE Ratio for today is calculated as:
Sangui Biotech International's share price for today is $0.0015.
Sangui Biotech International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sangui Biotech International EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Sangui Biotech International's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sangui Biotech International (Sangui Biotech International) Business Description
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGBI has been successfully added to your 